JAK inhibitors for refractory lymphoma

Kimura, Hiroshi

doi:10.18632/oncotarget.26054

Cited by 1 publication

(2 citation statements)

References 7 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The three-step therapy proposed by Kawa et al only provides better suppressed disease activities to bridge to allo-HSCT ( Sawada et al, 2017 ). Considering that even though CAEBV was regarded as a kind of EBV-LPD disease, it still has an inflammatory aspect, as hypercytokinemia is a common feature ( Arai, 2018 ; Kimura, 2018 ; Onozawa et al, 2018 ). And, in a precious report, we have already successfully treated one CAEBV patient with ruxolitinib with long-term survival in our center ( Jin et al, 2019 ).…”

Section: Discussionmentioning

confidence: 99%

“…According to a previous report, ruxolitinib was considered to be able to inhibit JAK activity by competitively inhibiting the ATP binding site of JAK kinase and may not only suppress the production of inflammatory cytokines of CAEBV patients but also decrease the viable cell number of EBV-positive NK or T cell lines and PBMCs by suppressing the phosphorylation of STAT3 in cells ( Kimura, 2018 ; Onozawa et al, 2018 ). However, in the observation of this study, it seems that the main role of ruxolitinib is concentrated in inhibiting the excessive inflammatory but is not able to reduce the number of living cells of EBV-positive cells.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ruxolitinib in Patients With Chronic Active Epstein-Barr Virus Infection: A Retrospective, Single-Center Study

Song

Wang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Chronic active Epstein-Barr virus (CAEBV) infection is one of the EBV-positive T- or NK-cell lymphoproliferative diseases. There is no safe and effective treatment currently and the only proven curable therapy is allogeneic hematopoietic stem cell transplantation (allo-HSCT). The JAK1/2 inhibitor, ruxolitinib, is now considered a novel therapy in inflammatory disease, and hypercytokinemia is an important feature of CAEBV.Method: All patients who suffered active CAEBV and were treated with ruxolitinib as compassionate use in our center from Sep 1, 2017, and Apr 30, 2019, were retrospectively analyzed.Results: In general, seven out of nine patients responded to ruxolitinib. Six out of seven patients became afebrile within 48 h. The AST/ALT level of three out of four patients decreased after ruxolitinib treatment. Two patients with cytopenia recovered. No significant decrease in the EBV-DNA copy number was observed (p = 0.161). For those seven patients who responded to ruxolitinib, the median continuing period in remission was 7.1 weeks (range, 3.4–101.0 weeks). Two patients achieved long-term stable remission with ruxolitinib monotherapy. None of these patients discontinued ruxolitinib due to the possible toxicity.Conclusion: Ruxolitinib is an effective and rather safe option for controlling the inflammatory symptoms of active CAEBV, especially in patients with CAEBV who have failed previous treatments or have relapsed. It can also play a promising role in improving the quality of daily life of patients and successfully bridging to allo-HSCT.

show abstract